What is the minimal amount of antibody required for assessment?

The typical requirement is at least 1 mg of purified antibody per candidate for the standard panel. The exact amount may vary based on the number of assays and replicates selected, and should be confirmed during project scoping.

Which antibody formats can be assessed?

Our standard panel supports monoclonal antibodies, bispecific antibodies, and antibody fragments (e.g., scFv, Fab). For non-standard formats, we recommend a consultation to tailor the assay panel.

How do you handle polyreactivity assessment?

We use a polyspecificity reagent (PSR) binding assay that measures cross-reactivity against a panel of biologically relevant molecules. This readout is combined with other orthogonal methods for a complete risk profile.

Can I request additional assays beyond the standard panel?

Yes, we offer customization. Common additions include hydrophobic interaction chromatography (HIC), accelerated stability studies, or forced degradation. Please discuss your needs during project scoping.

What is the turnaround time for results?

Turnaround is scoped per project based on candidate number and assay complexity. A typical timeline is discussed during the initial consultation and confirmed in the project agreement.

Are computational predictions enough to replace experiments?

No. Computational descriptors provide valuable early filtering, but we recommend combining them with experimental assays for a confident developability assessment. Our integrated service offers both layers.

Services

Online Inquiry

Name *

Email *

Subject *

Phone

Your Message

How Did You Hear About Us

Antibody Developability Assessment

Antibody Developability

Evaluate manufacturability, stability, and in vivo behavior of antibody candidates early with integrated biophysical assays and computational predictions.

AC-SINS self-interaction profiling
aHIC hydrophobicity analysis
nanoDSF thermal stability (Tagg / Tm)

Assess Your Candidates

Why Assess Developability Early?

Late-stage failures due to aggregation, viscosity, or polyreactivity are costly. Our platform identifies these risks early, enabling informed lead selection and reducing CMC surprises.

De-risk aggregation and self-association
Reduce late-stage CMC surprises
Data-driven lead prioritization

Rapid

Reproducible

Data-Driven

Our Approach

Integrated Biophysical and Computational Developability Assessment

We combine orthogonal assay readouts with machine-learning-derived descriptors to profile candidate robustness across multiple developability dimensions.

Biophysical Assay Panel

We express and purify antibodies (e.g., in CHO or HEK293 cells) and run a standard panel of developability assays to evaluate key risk factors.

AC-SINS to detect antibody self-association propensity
aHIC to measure hydrophobicity-driven retention
nanoDSF to determine Tagg and Tm for thermal stability
PSR binding assay to assess polyreactivity risk

Computational Descriptor Analysis

We compute sequence- and structure-based descriptors (e.g., from PROPERMAB, TA-DA) to predict developability properties in silico, complementing experimental data.

Sequence-based features for solubility and viscosity prediction
Structure-derived descriptors for conformational stability
Machine-learning models trained on clinical antibody data

Quality Control

Each assay is performed with validated reagents and controls to ensure reproducibility across batches and projects.

Statistical Rigor

Results are analyzed using appropriate replicates and statistical methods to support confident decision-making.

Biological Interpretability

Heatmaps and risk scores summarize multi-parametric data, highlighting candidates with high developability confidence.

Deliverables

What You Receive

A comprehensive developability report with raw data, processed metrics, and prioritized candidate list.

Data Deliverables

Raw assay data (AC-SINS shift, aHIC retention times, nanoDSF thermograms)
Processed metrics (Tagg, Tm, PSR binding index)
Computational developability scores (e.g., TA-DA score, PROPERMAB predictions)
Heatmap of risk parameters across all candidates

Reporting & Support

Comprehensive developability report with executive summary
Ranked candidate list with risk annotations
Interactive data visualization (optional)
Consultation call to discuss results and next steps

Service Scope

Tailored to Your Project Needs

Parameters are scoped per project to match candidate numbers, antibody formats, and desired depth of analysis.

Parameter	Typical Project Scope
Candidate Number	Scoped per project; typical 10–100 candidates
Expression System	CHO or HEK293, as agreed
Assay Panel	Standard: AC-SINS, aHIC, nanoDSF, PSR; optional HIC
Computational Descriptors	144+ sequence/structure features (TA-DA, PROPERMAB)
Replication	Minimum duplicates; triplicates for key assays
Sample Requirement	≥ 1 mg purified antibody per candidate (scoped per project)
QC Standards	Assay-specific positive/negative controls; data reviewed by project team
Data Format	PDF report + Excel or CSV data files

Workflow

From Candidate Submission to Developability Report

A streamlined process ensures timely and reproducible assessment of your antibody panel.

Candidate Receipt and QC

We receive purified antibody samples and verify concentration, purity, and buffer compatibility before initiating assays.

Biophysical Assay Execution

Our team runs AC-SINS, aHIC, nanoDSF, and PSR binding assays in parallel on all candidates under standardized conditions.

Computational Descriptor Computation

Sequence and structure-based features are computed and fed into our machine-learning models for developability prediction.

Data Integration and Analysis

Assay outputs and computational scores are integrated into a unified risk summary with normalization and statistical comparisons.

Report Preparation and Delivery

A comprehensive report including raw data, processed metrics, heatmaps, and candidate ranking is delivered for review and discussion.

Applications

Where Developability Assessment Delivers Value

Our service supports key decision points in antibody discovery and early development.

Prioritize Developable Leads

Compare multiple lead candidates side-by-side to select those with best manufacturability and in vivo behavior.

Rank candidates by combined risk scores
Identify high-risk candidates before expensive in vivo studies
Reduce attrition in later development

Guide Antibody Engineering

Use developability feedback to direct affinity maturation or humanization campaigns toward drug-like properties.

Assess the impact of sequence changes on stability and aggregation
Iterate design-build-test cycles with rapid assessment
Avoid introducing polyreactivity or hydrophobicity issues

Evaluate Different Antibody Formats

Compare monospecific, bispecific, and fragment formats for their developability profiles.

Assess self-association in non-standard formats
Determine the effect of additional binding domains on stability
Select the best format for further development

Benchmark Against Reference

Compare your molecule's developability to that of a reference antibody to guide biosimilar or biobetter strategies.

Identify differences in hydrophobicity or self-interaction
Assess thermal stability relative to innovator
Facilitate CQA-based development

FAQ

Frequently Asked Questions

Common questions about antibody developability assessment.

The typical requirement is at least 1 mg of purified antibody per candidate for the standard panel. The exact amount may vary based on the number of assays and replicates selected, and should be confirmed during project scoping.
Our standard panel supports monoclonal antibodies, bispecific antibodies, and antibody fragments (e.g., scFv, Fab). For non-standard formats, we recommend a consultation to tailor the assay panel.
We use a polyspecificity reagent (PSR) binding assay that measures cross-reactivity against a panel of biologically relevant molecules. This readout is combined with other orthogonal methods for a complete risk profile.
Yes, we offer customization. Common additions include hydrophobic interaction chromatography (HIC), accelerated stability studies, or forced degradation. Please discuss your needs during project scoping.
Turnaround is scoped per project based on candidate number and assay complexity. A typical timeline is discussed during the initial consultation and confirmed in the project agreement.
No. Computational descriptors provide valuable early filtering, but we recommend combining them with experimental assays for a confident developability assessment. Our integrated service offers both layers.

Scientific Literature

References

Arsiwala A, Bhatt R, van Niekerk L, et al. A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training. mAbs. 2025;17(1):2593055. View on PubMed
Amini S, Huang Y, Julian M, et al. Application of protein language models for antibody developability prediction. mAbs. 2026;18(1):2647489. View on PubMed
Negron C, Fang J, McPherson MJ, et al. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment. mAbs. 2022;14(1):2080628. View on PubMed
Li B, Luo S, Wang W, et al. PROPERMAB: an integrative framework for in silico prediction of antibody developability using machine learning. mAbs. 2025;17(1):2474521. View on PubMed
Wang S, Wang Y, Li Z, et al. Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment. mAbs. 2024;16(1):2374607. View on PubMed

Please kindly note that our products and services are for research use only.